1,401 results on '"Petrucelli, Leonard"'
Search Results
152. Arterial Thromboemboli in Hospitalized COVID-19 Patients: A Multi-center Experience
153. Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3
154. CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro
155. Differences in rate and trajectory of TDP-43-associated neurodegeneration in brains with and without frontotemporal lobar degeneration (S20.007)
156. In-vitro binding assessment of soluble and insoluble tau protein variants with [18F]-AV1451 and [18F]-MK6240
157. Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers
158. Comment on: Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood
159. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases
160. TARDBP mutations in Parkinson's disease
161. Additional file 1 of Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
162. Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease
163. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor
164. FTDP‐17 with Pick body‐like inclusions associated with a novel tau mutation, p.E372G
165. Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients
166. Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers.
167. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS
168. A novel tau mutation, p.K317N, causes globular glial tauopathy
169. Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia
170. Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model
171. Inflammasome mediated neuronal-microglial crosstalk: a therapeutic substrate for the familialC9orf72variant of the frontotemporal dementia/amyotrophic lateral sclerosis
172. Comprehensive preclinical evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9ORF72 disease
173. HDAC6 Interacts With Poly (GA) and Modulates its Accumulation in c9FTD/ALS
174. TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration
175. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress
176. Aberrant Cleavage of TDP-43 Enhances Aggregation and Cellular Toxicity
177. CHIP Regulates Leucine-Rich Repeat Kinase-2 Ubiquitination, Degradation, and Toxicity
178. Akt and CHIP Coregulate Tau Degradation through Coordinated Interactions
179. Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations
180. Clinical value of CSF tau, p‐tau181, neurogranin and neurofilaments in familial frontotemporal lobar degeneration
181. Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains
182. Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders
183. Developing biomarkers of TDP‐43‐related splicing dysfunction in frontotemporal dementia
184. Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G 4 C 2 ) repeat expansion in vitro and in vivo ALS models
185. A Small Molecule Exploits Hidden Structural Features within the RNA Repeat Expansion That Causes c9ALS/FTD and Rescues Pathological Hallmarks
186. Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy
187. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease
188. Staging TDP-43 pathology in Alzheimer’s disease
189. Mechanisms of toxicity in C9FTLD/ALS
190. Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration
191. C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells
192. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor
193. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood
194. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS
195. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3
196. Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72
197. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model
198. TAR DNA-binding protein 43 and pathological subtype of Alzheimerʼs disease impact clinical features
199. Targeting Aβ and tau in Alzheimer's disease, an early interim report
200. Microglial lysosome dysfunction contributes to white matter pathology and TDP-43 proteinopathy in GRN-associated FTD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.